Hangzhou Tigermed Consulting Co., Ltd (SHE: 300347)

Market Cap	48.68B
Revenue (ttm)	6.80B
Net Income (ttm)	958.67M
Shares Out	861.29M
EPS (ttm)	1.11
PE Ratio	54.96
Forward PE	31.54
Dividend	0.57 (0.93%)
Ex-Dividend Date	Jul 12, 2024

Volume	5,223,273
Open	64.51
Previous Close	62.19
Day's Range	60.45 - 64.51
52-Week Range	36.12 - 82.79
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About Hangzhou Tigermed Consulting

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 9,701
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2023, Hangzhou Tigermed Consulting's revenue was 7.38 billion, an increase of 4.21% compared to the previous year's 7.09 billion. Earnings were 2.02 billion, an increase of 0.91%.